ACA Stock Analysis: Arcosa | NYSE
Engineering & Construction | NYSE, USA | Market Cap: 7.139m USD | 12M Return: 61.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 95.9M
EPS Trend: 78.1%
Qual. Beats: 5
Rev. Trend: 98.7%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arcosa, Inc. (NYSE: ACA) is a U.S.-based industrial company that supplies infrastructure-related products and solutions across three segments: Construction Products (natural and recycled aggregates, specialty materials, and construction site support equipment such as trench shields and shoring), Engineered Structures (utility poles, wind towers, traffic and lighting structures, and telecommunication structures), and Transportation Products (inland barges, barge covers, winches, and marine hardware). The company serves residential, non-residential, and infrastructure construction markets, electricity transmission and distribution, wind power generation, highway construction, wireless communications, and commercial marine transportation. Arcosa was incorporated in 2018 and is headquartered in Dallas, Texas.
The company operates in the GICS Construction & Engineering sub-industry, a sector that includes manufacturers of building products, infrastructure components, and engineering services suppliers. Listed on the NYSE since its October 2018 IPO, Arcosa is structured as a mid-cap industrial with a market capitalization of approximately $6.3 billion, and its business model spans manufactured products rather than direct construction services.
- Federal infrastructure bill lifts aggregates volumes and pricing
- Wind tower backlog grows on renewable energy demand
- Barge demand recovers with US grain export cycle
| Net Income: 222.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.22 > 1.0 |
| NWC/Revenue: 22.80% < 20% (prev 19.26%; Δ 3.55% < -1%) |
| CFO/TA 0.08 > 3% & CFO 413.7m > Net Income 222.6m |
| Net Debt (1.37b) to EBITDA (564.1m): 2.42 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 22.77% > 18% (prev 20.32%; Δ 2.45% > 0.5%) |
| Asset Turnover: 57.48% > 50% (prev 52.76%; Δ 4.71% > 0%) |
| Interest Coverage Ratio: 3.27 > 6 (EBIT TTM 341.2m / Interest Expense TTM 104.5m) |
| A: 0.13 (Total Current Assets 1.13b - Total Current Liabilities 489.6m) / Total Assets 4.89b |
| B: 0.20 (Retained Earnings 982.7m / Total Assets 4.89b) |
| C: 0.07 (EBIT TTM 341.2m / Avg Total Assets 4.91b) |
| D: 1.17 (Book Value of Equity 2.63b / Total Liabilities 2.26b) |
| Altman-Z'' = 3.21 = A |
| DSRI: 0.89 (Receivables 413.9m/427.6m, Revenue 2.82b/2.60b) |
| GMI: 0.89 (GM 20.32% / 22.77%) |
| AQI: 0.93 (AQ_t 0.34 / AQ_t-1 0.37) |
| SGI: 1.08 (Revenue 2.82b / 2.60b) |
| TATA: -0.04 (NI 222.6m - CFO 413.7m) / TA 4.89b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 145.38 with a total of 685,316 shares traded. Over the past week, the price has changed by +0.06%, over one month by +17.68%, over three months by +32.10% and over the past year by +61.82%.
Current recommended Stop Loss: 141.80 (which is 2.5% or 1.3 ATR below the current price).
Arcosa has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ACA.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 145.5 | 0.1% |
P/E Trailing = 32.5235
P/E Forward = 36.1011
P/S = 2.4554
P/B = 2.6837
P/EG = 2.2539
Revenue TTM = 2.82b USD
EBIT TTM = 341.2m USD
EBITDA TTM = 564.1m USD
Long Term Debt = 1.51b USD (from longTermDebt, last quarter)
Short Term Debt = 8.00m USD (from shortTermDebt, last quarter)
Debt = 1.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.37b USD (calculated: Debt 1.52b - CCE 153.2m)
Enterprise Value = 8.51b USD (7.14b + Debt 1.52b - CCE 153.2m)
Interest Coverage Ratio = 3.27 (Ebit TTM 341.2m / Interest Expense TTM 104.5m)
EV/FCF = 35.65x (Enterprise Value 8.51b / FCF TTM 238.6m)
FCF Yield = 2.80% (FCF TTM 238.6m / Enterprise Value 8.51b)
FCF Margin = 8.45% (FCF TTM 238.6m / Revenue TTM 2.82b)
Net Margin = 7.88% (Net Income TTM 222.6m / Revenue TTM 2.82b)
Gross Margin = 22.77% ((Revenue TTM 2.82b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 21.15% (prev 22.85%)
Tobins Q-Ratio = 1.74 (Enterprise Value 8.51b / Total Assets 4.89b)
Interest Expense / Debt = 6.87% (Interest Expense 104.5m / Debt 1.52b)
Taxrate = 12.08% (28.6m / 236.7m)
NOPAT = 300.0m (EBIT 341.2m * (1 - 12.08%))
Current Ratio = 2.31 (Total Current Assets 1.13b / Total Current Liabilities 489.6m)
Debt / Equity = 0.58 (Debt 1.52b / totalStockholderEquity, last quarter 2.63b)
Debt / EBITDA = 2.42 (Net Debt 1.37b / EBITDA 564.1m)
Debt / FCF = 5.73 (Net Debt 1.37b / FCF TTM 238.6m)
Total Stockholder Equity = 2.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.53% (Net Income 222.6m / Total Assets 4.89b)
RoE = 8.60% (Net Income TTM 222.6m / Total Stockholder Equity 2.59b)
RoCE = 8.32% (EBIT 341.2m / Capital Employed (Equity 2.59b + L.T.Debt 1.51b))
RoIC = 7.03% (NOPAT 300.0m / Invested Capital 4.27b)
WACC = 10.03% (E(7.14b)/V(8.66b) * Re(10.88%) + D(1.52b)/V(8.66b) * Rd(6.87%) * (1-Tc(0.12)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 61.28 | Cagr: 0.46%
[DCF] Terminal Value 68.94% ; FCFF base≈243.8m ; Y1≈234.3m ; Y5≈227.3m
[DCF] Fair Price = 28.99 (EV 2.78b - Net Debt 1.37b = Equity 1.41b / Shares 48.8m; r=10.03% [WACC]; 5y FCF grow -5.13% → 2.50% )
EPS Correlation: 78.15 | EPS CAGR: 17.18% | SUE: 1.94 | # QB: 5
Revenue Correlation: 98.67 | Revenue CAGR: 10.57% | SUE: -2.43 | # QB: -1
EPS current Quarter (2026-06-30): EPS=1.18 | Chg30d=-2.67% | Revisions=-17% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.56 | Chg30d=+0.97% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=4.38 | Chg30d=+1.80% | Revisions=+17% | GrowthEPS=-1.9% | GrowthRev=-9.1%
EPS next Year (2027-12-31): EPS=5.08 | Chg30d=+0.69% | Revisions=+17% | GrowthEPS=+16.0% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +13% (up=7, down=5)